{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:38:27Z","timestamp":1789983507672,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,2,27]],"date-time":"2014-02-27T00:00:00Z","timestamp":1393459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.tranon.2014.02.007","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T01:46:20Z","timestamp":1393897580000},"page":"221-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Antiangiogenic Therapy Using Sunitinib Combined with Rapamycin Retards Tumor Growth But Promotes Metastasis"],"prefix":"10.1016","volume":"7","author":[{"given":"Tao","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.tranon.2014.02.007_bb0005","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2537","article-title":"Tumor angiogenesis: molecular pathways and therapeutic targets","volume":"17","author":"Weis","year":"2011","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.tranon.2014.02.007_bb0010","first-page":"99","article-title":"SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types","volume":"59","author":"Fong","year":"1999","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.tranon.2014.02.007_bb0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"Paez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"issue":"7092","key":"10.1016\/j.tranon.2014.02.007_bb0020","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature04871","article-title":"Hypoxia signalling in cancer and approaches to enforce tumour regression","volume":"441","author":"Pouyssegur","year":"2006","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.tranon.2014.02.007_bb0025","first-page":"4693","article-title":"Overexpression of hypoxia-inducible factor 1\u03b1 is a marker for an unfavorable prognosis in early- stage invasive cervical cancer","volume":"60","author":"Birner","year":"2000","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.tranon.2014.02.007_bb0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ncb1691","article-title":"Direct regulation of TWIST by HIF-1\u03b1 promotes metastasis","volume":"10","author":"Yang","year":"2008","journal-title":"Nat Cell Biol"},{"issue":"7","key":"10.1016\/j.tranon.2014.02.007_bb0035","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2004.06.006","article-title":"Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis","volume":"117","author":"Yang","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2014.02.007_bb0040","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/phar macodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tranon.2014.02.007_bb0045","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","article-title":"Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"6","author":"Burstein","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tranon.2014.02.007_bb0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.canlet.2008.05.007","article-title":"Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts","volume":"2","author":"Cumashi","year":"2008","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.tranon.2014.02.007_bb0055","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1073\/pnas.1018866109","article-title":"Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia","volume":"109","author":"Conley","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7092","key":"10.1016\/j.tranon.2014.02.007_bb0060","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"issue":"7396","key":"10.1016\/j.tranon.2014.02.007_bb0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature10912","article-title":"The translational landscape of mTOR signalling steers cancer initiation and metastasis","volume":"485","author":"Hsieh","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.tranon.2014.02.007_bb0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/01.RES.86.1.4","article-title":"Akt takes center stage in angiogenesis signaling","volume":"86","author":"Dimmeler","year":"2000","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.tranon.2014.02.007_bb0075","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1172\/JCI24726","article-title":"Akt1\/protein kinase B\u03b1 is critical for ischemic and VEGF-mediated angiogenesis","volume":"115","author":"Ackah","year":"2005","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.tranon.2014.02.007_bb0080","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccr.2006.07.003","article-title":"Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin","volume":"10","author":"Phung","year":"2006","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.tranon.2014.02.007_bb0085","first-page":"451","article-title":"Differential ffects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells","volume":"3","author":"Edinger","year":"2003","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.tranon.2014.02.007_bb0090","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.tranon.2014.02.007_bb0095","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/sj.bjc.6602162","article-title":"Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer","volume":"91","author":"Chan","year":"2004","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2014.02.007_bb0100","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","article-title":"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.tranon.2014.02.007_bb0105","doi-asserted-by":"crossref","first-page":"9277","DOI":"10.1158\/0008-5472.CAN-10-2029","article-title":"Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors","volume":"70","author":"Escorcia","year":"2010","journal-title":"Cancer Res"},{"issue":"7347","key":"10.1016\/j.tranon.2014.02.007_bb0110","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.tranon.2014.02.007_bb0115","doi-asserted-by":"crossref","first-page":"F1214","DOI":"10.1152\/ajprenal.00710.2010","article-title":"Albumin-induced epithelial-mesenchymal transition and ER stress are regulated through a common ROS-c-Src kinase-mTOR pathway: effect of imatinib mesylate","volume":"300","author":"Lee","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"10.1016\/j.tranon.2014.02.007_bb0120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10585-012-9526-9","article-title":"Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma","volume":"30","author":"Hong","year":"2013","journal-title":"Clin Exp Metastasis"},{"issue":"6","key":"10.1016\/j.tranon.2014.02.007_bb0125","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.tranon.2014.02.007_bb0130","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ccr.2004.08.031","article-title":"Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis","volume":"6","author":"Yang","year":"2004","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.tranon.2014.02.007_bb0135","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1182\/blood-2008-02-137430","article-title":"Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells","volume":"112","author":"Ohtani","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2014.02.007_bb0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/0008-5472.CAN-11-2089","article-title":"mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer","volume":"73","author":"Pool","year":"2013","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.tranon.2014.02.007_bb0145","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2004-03-1109","article-title":"Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues","volume":"104","author":"Murdoch","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.tranon.2014.02.007_bb0150","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1158\/0008-5472.CAN-11-2905","article-title":"Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition","volume":"72","author":"Gao","year":"2012","journal-title":"Cancer Res"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523314000084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523314000084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:29:02Z","timestamp":1761834542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523314000084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1936523314000084"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2014.02.007","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiangiogenic Therapy Using Sunitinib Combined with Rapamycin Retards Tumor Growth But Promotes Metastasis","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2014.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Neoplasia Press, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}